DrugPatentWatch Database Preview
RIOMET Drug Profile
Which patents cover Riomet, and what generic alternatives are available?
Riomet is a drug marketed by Sun Pharm Inds Ltd and is included in one NDA. There is one patent protecting this drug and one Paragraph IV challenge.
This drug has eighteen patent family members in eighteen countries.
The generic ingredient in RIOMET is metformin hydrochloride. There are forty-nine drug master file entries for this compound. One hundred and eleven suppliers are listed for this compound. Additional details are available on the metformin hydrochloride profile page.
Summary for RIOMET
| International Patents: | 18 |
| US Patents: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 2 |
| Bulk Api Vendors: | 118 |
| Clinical Trials: | 30 |
| Patent Applications: | 38 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for RIOMET |
| DailyMed Link: | RIOMET at DailyMed |
Pharmacology for RIOMET
| Drug Class | Biguanide |
Medical Subject Heading (MeSH) Categories for RIOMET
Synonyms for RIOMET
| (E)-2-carbamimidoyl-1,1-dimethylguanidine hydrochloride |
| 1-dimethylbiguanide hydrochloride |
| 1,1-Dimethylbiguanide hydrochloride |
| 1,1-Dimethylbiguanide hydrochloride, 97% |
| 1,1-Dimethylbiguanide monohydrochloride |
| 1,1-Dimethylbiguanide, Hydrochloride |
| 1115-70-4 |
| 144377-16-2 |
| 15537-72-1 |
| 3-(diaminomethylene)-1,1-dimethyl-guanidine hydrochloride |
| 3-(diaminomethylidene)-1,1-dimethylguanidine hydrochloride |
| 3-carbamimidoyl-1,1-dimethylguanidine;hydrochloride |
| 56258-19-6 |
| 786Z46389E |
| AB0004717 |
| AB1009370 |
| AC-2075 |
| AC1L23D5 |
| ACMC-20ap7s |
| AI3-51264 |
| AK163172 |
| AKOS015894259 |
| AN-8747 |
| API0003318 |
| Apo-Metformin |
| AX8041182 |
| BB_SC-5098 |
| BC206669 |
| Benofomin |
| BG0401 |
| BIGUANIDE, 1,1-DIMETHYL-, HYDROCHLORIDE |
| Biguanide, 1,1-dimethyl-, monohydrochloride |
| Biguanide, 1,1-dimethyl-, monohydrochloride (8CI) |
| Biguanide,1-dimethyl-, monohydrochloride |
| Biocos |
| BP-12830 |
| C4H11N5.HCl |
| C4H12ClN5 |
| CAS-1115-70-4 |
| CCG-208004 |
| CHEBI:6802 |
| CHEMBL1703 |
| Cidophage |
| CS-1851 |
| CTK8C6229 |
| D 15095 |
| D.B.I |
| D.B.I. |
| D00944 |
| Dabex |
| DB-018697 |
| Denkaform |
| Dextin |
| Diabefagos |
| Diaberit |
| Diabesin |
| Diabetex |
| Diabetmin |
| Diaformin |
| Diamin |
| Diaphage |
| Diformin |
| Diformin Retard |
| Dimethylbiguanide hydrochloride |
| DMBG hydrochloride |
| DMGG hydrochloride |
| DSSTox_CID_17246 |
| DSSTox_GSID_37246 |
| DSSTox_RID_79314 |
| DTXSID9037246 |
| EC 214-230-6 |
| EINECS 214-230-6 |
| F2173-0894 |
| Fornidd |
| Fortamet |
| FT-0628265 |
| Geamet |
| Glibomet |
| Glucofago |
| Glucoform |
| Glucoliz |
| Glucomet |
| Glucomine |
| Gluconil |
| Glucophage |
| Glucophage (TN) |
| Glucophage 850 |
| Glucophage Forte |
| Glucophage Retard |
| Glucophage XR |
| Glucophage-Mite |
| Gluformin |
| Glupermin |
| Glyciphage |
| Glycoran |
| Glyformin |
| GP2747 |
| Haurymellin hydrochloride |
| HMS1568A09 |
| HMS1922H14 |
| HSDB 7080 |
| HY-17471A |
| I05-0228 |
| I14-7880 |
| I506 |
| Imidodicarbonimidic diamide, N,N-dimethyl-, monohydrochloride |
| Imidodicarbonimidic diamide, N,N-dimethyl-, monohydrochloride (9CI) |
| Imidodicarbonimidic diamide,N-dimethyl-, monohydrochloride |
| Islotin retard |
| J10020 |
| J10377 |
| Jsp000870 |
| KS-000006B5 |
| KS-1272 |
| KSC926E2T |
| LA 6023 |
| LA 6063 |
| LS-43900 |
| M-2922 |
| M2009 |
| MCULE-9784059944 |
| Meglucon |
| Meguan |
| Mescorit |
| Metbay |
| Metforal |
| Metformin (hydrochloride) |
| Metformin HCL |
| Metformin HCl ER |
| Metformin HCl(Glucophage) |
| Metformin hydrochloride |
| Metformin hydrochloride (Glucophage) |
| Metformin hydrochloride (JP17/USP) |
| Metformin hydrochloride [USAN:USP:JAN] |
| Metformin hydrochloride [USAN] |
| Metformin Hydrochloride 1.0 mg/ml in Methanol (as free base) |
| Metformin hydrochloride, British Pharmacopoeia (BP) Reference Standard |
| Metformin hydrochloride, European Pharmacopoeia (EP) Reference Standard |
| Metformin hydrochloride, pharmaceutical secondary standard; traceable to USP and PhEur |
| Metformin hydrochloride, United States Pharmacopeia (USP) Reference Standard |
| Metformin monohydrochloride |
| Metiguanide monohydrochloride |
| Metolmin |
| Metomin |
| MFCD00012582 |
| MLS000028493 |
| MLS002222221 |
| MolPort-000-771-764 |
| MolPort-039-227-817 |
| N-[amino(dimethylamino)methylidene]guanidine hydrochloride |
| N,N-Dimethylbiguanide hydrochloride |
| N,N-dimethylimidodicarbonimidic diamide hydrochloride |
| N,N-Dimethylimidodicarbonimidic diamine |
| N',N'-dimethylbiguanide hydrochloride |
| N1,N1-Dimethylbiguanide hydrochloride |
| NCGC00016564-01 |
| NCGC00016564-06 |
| NCGC00095185-01 |
| NCGC00095185-02 |
| Novo-Metformin |
| NSC 91485 |
| NSC-759262 |
| NSC-91485 |
| NSC759262 |
| NSC91485 |
| OETHQSJEHLVLGH-UHFFFAOYSA-N |
| OR145246 |
| Pharmakon1600-01505814 |
| Prestwick_519 |
| Q-201360 |
| Risidon |
| RP22848 |
| RTR-002281 |
| s1950 |
| SC-17468 |
| SCHEMBL10325580 |
| SCHEMBL22977 |
| Siamformet |
| SMR000058277 |
| SPECTRUM1505814 |
| ST24048701 |
| SY001217 |
| Thiabet |
| TL8000340 |
| Tox21_110498 |
| Tox21_110498_1 |
| TR-002281 |
| TRA0069243 |
| UNII-786Z46389E |
| Walaphage |
| Z2244578658 |
US Patents and Regulatory Information for RIOMET
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sun Pharm Inds Ltd | RIOMET | metformin hydrochloride | SOLUTION;ORAL | 021591-001 | Sep 11, 2003 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | Y | ➤ Sign Up | |||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
Paragraph IV (Patent) Challenges for RIOMET
| Drugname | Dosage | Strength | RLD | Date |
|---|---|---|---|---|
| ➤ Subscribe | Oral Solution | 500 mg/5 mL | ➤ Subscribe | ➤ Sign Up |
International Patents for RIOMET
| Country | Document Number | Estimated Expiration |
|---|---|---|
| China | 1635881 | ➤ Sign Up |
| Slovakia | 2102003 | ➤ Sign Up |
| Canada | 2416767 | ➤ Sign Up |
| Croatia | P20030161 | ➤ Sign Up |
| Hungary | 0302700 | ➤ Sign Up |
| Brazil | 0113102 | ➤ Sign Up |
| European Patent Office | 1387675 | ➤ Sign Up |
| Country | Document Number | Estimated Expiration |
Supplementary Protection Certificates for RIOMET
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| 2014000071 | Germany | ➤ Sign Up | PRODUCT NAME: KOMBINATION VON DAPAGLIFLOZIN ODER EINEM PHARMAZEUTISCH VERTRAEGLICHEN SALZ DAVON, UND METFORMIN ODER EINEM PHARMAZEUTISCH VERTRAEGLICHEN SALZ DAVON, GESCHUETZT DURCH DAS GRUNDPATENT EP 1 506 211; REGISTRATION NO/DATE: EU/1/13/900 20140116 |
| 2014 00037 | Denmark | ➤ Sign Up | PRODUCT NAME: ET KOMBINATIONSPRODUKT AF DAPAGLIFLOZIN ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF, HERUNDER DAPAGLIFLOZINPROPANDIOLMONOHYDRAT OG METFORMIN ELLER SALTE DERAF, HERUNDER METFORMINHYDROCHLORID; REG. NO/DATE: EU/1/13/900 20140116 |
| 2008013,C1412357 | Lithuania | ➤ Sign Up | PRODUCT NAME: SITAGLIPTINUM PHOSPHAS MONOHYDRICUS, METFORMINI HYDROCHLORIDUM; REGISTRATION NO/DATE: EU/1/08/455/001 - EU/1/08/455/014 20080716 |
| 2014 00037 | Denmark | ➤ Sign Up | PRODUCT NAME: ET KOMBINATIONSPRODUKT AF DAPAGLIFLOZIN ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF, HERUNDER DAPAGLIFLOZINPROPANDIOLMONOHYDRAT OG METFORMIN ELLER SALTE DERAF, HERUNDER METFORMINHYDROCHLORID; REG. NO/DATE: EU/1/13/900 20140116 |
| 1730131/02 | Switzerland | ➤ Sign Up | PRODUCT NAME: EMPAGLIFLOZIN UND METFORMINHYDROCHLORID; REGISTRATION NO/DATE: SWISSMEDIC 65570 12.11.2015 |
| 2008013 | Lithuania | ➤ Sign Up | PRODUCT NAME: SITAGLIPTINUM PHOSPHAS MONOHYDRICUS, METFORMINI HYDROCHLORIDUM; REG. NO/DATE: EU/1/08/455/001-014 20080716 |
| C/GB08/040 | United Kingdom | ➤ Sign Up | PRODUCT NAME: SITAGLIPTIN OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, IN PARTICULAR THE MONOPHOSPHATE, PLUS METFORMIN OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, IN PARTICULAR THE HYDROCHLORIDE.; REGISTERED: CH 58450 01-03 20080408; UK EU/1/08/455/001 20080716; UK EU/1/08/455/002 20080716; UK EU/1/08/455/003 20080716; UK EU/1/08/455/004 20080716; UK EU/1/08/455/005 20080716; UK EU/1/08/455/006 20080716; UK EU/1/08/455/007 20080716; UK EU/1/08/455/008 20080716; UK EU/1/08/455/009 20080716; UK EU/1/08/455/010 20080716; UK EU/1/08/455/011 20080716; UK EU/1/08/455/012 20080716; UK EU/1/08/455/013 20080716; UK EU/1/08/455/014 20080716 |
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
